Description

VIR-165 is a modified form of virus inhibitory peptide (VIRIP) that binds the fusion peptide of the gp41 subunit and prevents its insertion into the target membrane. VIRIP inhibits a wide variety of human immunodeficiency virus type 1 (HIV-1) strains[1].—COVID-19-anti-virus–C109H156N22O25S2—-[1]Münch J, et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell. 2007 Apr 20;129(2):263-75.|[2]Eggink D, et al. HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike. J Virol. 2016 Nov 14;90(23):10587-10599.–943790-62-3–2238.67—-O=C1[C@@]2([H])N(CCC2)C([C@](NC([C@@H](NC([C@H](CSSC[C@H](NC([C@@]3([H])N1CCC3)=O)C(N[C@H](C(N[C@@H](C)C(N[C@H](C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N4[C@@H](CCC4)C(N[C@H](C(N[C@@H](C(C)C)C(N[C@H](C(O)=O)CC5=CC=CC=C5)=O)=O)CC6=CC=CC=C6)=O)=O)=O)=O)CC7=CC=CC=C7)=O)=O)CC8=CC=CC=C8)=O)NC([C@H]9N(CCC9)C([C@H]([C@@H](C)CC)NC([C@H](C)NC([C@H](CCC(O)=O)NC([C@@H](N)CC(C)C)=O)=O)=O)=O)=O)=O)CO)=O)([H])[C@@H](C)CC)=O–Infection–10 mM in DMSO–HIV—-Anti-infection–Peptides